Table 2

Incidence, mortality and utility of long term complications due to high-dose (HD) or standard-dose (SD) chemotherapy for non-seminomatous germ cell cancer.

Morbidity

References

Incidence

Suspected agent

Mortality

Change in mortality³

Utility⁴

Change in morbidity⁵

SD

HD

Therapy related leukaemia

[10, 22, 23]

0.5%

1.5%

Etoposide (< 2 g/m², > 2 g/m²)

70%

0.7%

0.90

0.03%

Vascular toxicity

[10, 16, 24, 25]

Raynaud's phenomenon

25%

>25%

Bleomycin

-

-

Cardiovascular disease

7%

10%

Cisplatin

10%

0.3%

0.7

0.81%

Neurotoxicity

[5, 10, 21]

Peripheral neuropathy

4%

5%

Cisplatin

-

-

Ototoxicity

5%

65%

Cisplatin (<400 mg/m², > 400 mg/m²)

-

-

Nephrotoxicity

[5, 10, 16]

Renal failure

1%

4%

Cisplatin

0.6

1.2%

Hypertension

10%

24%

Cisplatin (<400 mg/m², > 400 mg/m²)

0.99

0.14%

Gonadal toxicity

[10, 16, 26, 41]

Infertility¹

50%

>50%

Cisplatin

Sexual functioning²

15%

27%

0.92

0.96%

Total

1%

3.14%

¹ oligospermia/azoospermia

² sexual dissatisfaction

³ Change in mortality calculated as (incidence_HD-CT - incidence_SD-CT) × fatality

⁴ Utility ranges from 0–1 and is a measure of health related quality of life

⁵ Change in morbidity calculated as (incidence_HD-CT - incidence_SD-CT) × (1-U) × (1-fatality).

van Dijk et al. BMC Medical Informatics and Decision Making 2008 8:1   doi:10.1186/1472-6947-8-1